Transplantation, AutologousHematopoietic Stem Cell TransplantationStem Cell TransplantationAntibodies, Monoclonal, Murine-DerivedAntineoplastic Combined Chemotherapy ProtocolsCyclophosphamidePeripheral Blood Stem Cell TransplantationCombined Modality TherapyTreatment OutcomeMultiple MyelomaMelphalanVincristineTransplantation, HomologousTransplantation ConditioningDisease-Free SurvivalDoxorubicinRemission InductionPrednisoneSalvage TherapyLymphoma, Mantle-CellStem CellsEtoposideSurvival RateLymphoma, Large B-Cell, DiffuseSurvival AnalysisLymphoma, Non-HodgkinAntibodies, MonoclonalLymphoma, FollicularHodgkin DiseaseRecurrenceCytarabineMyeloablative AgonistsPrognosisCarmustineAntineoplastic AgentsHematopoietic Stem Cell MobilizationBone Marrow TransplantationGraft vs Host DiseaseThiotepaBone Marrow PurgingRetrospective StudiesChemotherapy, AdjuvantHematologic NeoplasmsLymphoma, B-CellWhole-Body IrradiationAmyloidosisDexamethasoneBoronic AcidsHematopoietic Stem CellsFollow-Up StudiesAntigens, CD20BusulfanPyrazinesCisplatinAntineoplastic Agents, AlkylatingGraft SurvivalIfosfamideInduction ChemotherapyAntigens, CD34Lymphoma, T-Cell, PeripheralTime FactorsAutograftsThalidomideLiver TransplantationLymphomaGranulocyte Colony-Stimulating FactorLeukapheresisMesenchymal Stem Cell TransplantationMaintenance ChemotherapyNeoplasm, ResidualPodophyllotoxinNeoplasm Recurrence, LocalAntibodies, Monoclonal, HumanizedNeoplasm StagingLeukemia, Myeloid, AcuteTransplantation ChimeraDrug Administration ScheduleMitoxantroneTissue DonorsCarboplatinCord Blood Stem Cell TransplantationCell TransplantationKidney TransplantationProspective StudiesNeoplasms, Second PrimaryIdarubicinMyelodysplastic SyndromesEnteropathy-Associated T-Cell LymphomaImmunosuppressive AgentsEmbryonic Stem CellsLeukemia, Plasma CellInfusions, SpinalNeutropeniaBlood Component RemovalFeasibility StudiesAdult Stem CellsBreast NeoplasmsVidarabineFatal OutcomeHistocompatibility Testing